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ABSTRACT
Pulmonary neuroendocrine tumors (PNTs) comprise different neoplasms, 
ranging from low grade carcinoids to the highly malignant small cell lung cancers. 
Several studies identified the cytoskeleton protein Filamin A (FLNA) as determinant 
in cancer progression and metastasis, but the role of FLNA in PNT aggressiveness and 
progression is still unknown.
We evaluated FLNA expression in PNTs with different grade of differentiation, 
the role of FLNA in cell proliferation, colony formation, angiogenesis, cell adhesion 
and migration in PNT cell line (H727 cells) and primary cultures and the possible 
interaction between FLNA and Rap1-GTPase. FLNA is highly expressed in PNTs with 
high malignant grade. FLNA silencing reduces cyclin D1 levels (-51±5, p<0.001) and 
cell proliferation in PNT cells (-37±4, p<0.05), colony formation and VEGF expression 
(-39±9%, p<0.01) in H727 cells.
FLNA and Rap1 co-localize in cellular protrusions and FLNA silencing up-regulates 
Rap1 expression (+73±18%, p<0.01).
Rap1 silencing prevents cell adhesion increase (+43%±18%, p<0.01) and cell 
migration decrease (-56±7%, p<0.01) induced by FLNA silencing, without affecting 
cell proliferation reduction. In conclusion, FLNA is implicated in PNT progression, in 
part through Rap1, thus providing a potential diagnostic and therapeutic target.
INTRODUCTION
Pulmonary neuroendocrine tumors (PNTs) comprise 
a spectrum of neoplasms, ranging from low grade typical 
carcinoids via the intermediate grade atypical carcinoids 
to the highly malignant small cell lung cancers [1]. 
Since no large phase II/III trials for PNTs have been 
published, surgery remains the treatment of choice [2, 
3]. Different studies clearly support a role of a widely-
expressed cytoskeleton protein, Filamin-A (FLNA), in 
cancer progression and metastasis [4]. In fact, FLNA is 
overexpressed in multiple types of tumors, including 
prostate, breast, lung cancer, hemangiomas, colon cancer, 
melanoma, neuroblastoma, squamous cell carcinoma, 
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hepatic cholangiocarcinoma, suggesting a possible 
correlation with FLNA and cancer aggressiveness [5, 6].
FLNA is crucial for cell shape modulation and 
motility: it crosslinks cortical actin filaments into a dynamic 
three-dimensional structure [7] and anchors actin filaments 
to cell-extracellular matrix adhesion sites. Moreover, FLNA 
is known to scaffold over 90 protein-binding partners, 
involved in receptor activation, cell migration and adhesion, 
cell proliferation, inflammation and tumorigenesis [8–10]. 
Increasing evidence demonstrated that FLNA is pivotal for 
regulation of matrix cytoskeleton signaling by binding to 
integrins, which are essential for maintaining directed cell 
migration and adhesion [6], and for coordination of GTPase 
signaling factors, leading the formation of lamellipodia 
and filopodia [11]. In this respect, Rap1 small GTPase is 
involved in the control of cell migration and adhesion by 
enhancing integrin-mediated cell–matrix attachment in 
several cell types [12].
In addition, Filamin-A (FLNA) physically interacts 
with HIF-1α [13], that regulates angiogenesis through 
upregulation of vascular endothelial growth factor (VEGF) 
[14, 15].
To date, the role of FLNA and the molecular 
mechanism involved in PNT aggressiveness and 
progression is still unknown. In order to establish whether 
FLNA is involved or not in this phenomenon we evaluated 
the correlation of FLNA expression patterns in different 
PNT stages, we assessed the role of this cytoskeleton 
protein in influencing cell mobility, cell proliferation, 
colony formation, angiogenesis, focusing on the potential 
interaction between FLNA and Rap1.
RESULTS
Filamin A expression correlates with different 
PNTs stages
In order to study the possible relationship 
between FLNA and tumor aggressiveness, we 
evaluated FLNA expression in different PNT stages by 
immunohistochemistry using PNT samples, ranging 
from low grade typical carcinoids (TP) (n=40), atypical 
carcinoids (AT) (n=11) to the highly malignant large cell 
lung carcinoma (LCLC) (n=10) and small cell lung cancers 
(SCLC) (n=5). We found a correlation between clinical 
phenotype of different P-NETs and immunohistochemical 
score of FLNA. As shown in Figure 1A FLNA is expressed 
in the cytoplasm of PNT tissues and its expression being 
higher in PNTs with higher malignant grade. In particular, 
FLNA expression is significantly increased in LCLC 
and SCLC cells compared to TC and AC cells (one way 
ANOVA, followed by Bonferroni post hoc test, **** 
p<0.001, ** p<0.01) (Figure 1B). As shown in Table 1, 
FLNA expression is significantly correlated with age, 
gender, T and N staging (* p<0.05; ** p<0.01). The 
pathological findings of 65 PNTs included in the IHC 
study are described in the Supplementary Table 1.
FLNA promotes PNTs cell proliferation and 
colony formation
To further investigate the role of FLNA in tumor 
development and progression, we evaluated whether 
Figure 1: (A) Representative pictures of immunohistochemistry for FLNA in different PNTs (20X magnification). (B) Graph of FLNA 
expression obtained from the average of immunohistochemistry scores in different PNTs. FLNA immunoreactivity was graded taking 
into account both the percentage of positive cells (0–30%=1; 31–60% = 2; 61–100% = 3) and the staining intensity (0=absence of 
immunoreactivity; 1= weak; 2= medium intensity; and 3= strong reactivity). TC= typical carcinoid, AC= atypical carcinoid, LCLC=large 
cell lung carcinoma; SCLC= small cell lung carcinoma.
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FLNA is involved in PNT cell proliferation. Thus, we 
silenced FLNA expression in PNTs to evaluate cyclin 
D1 expression. As shown, 80% decrease in FLNA levels 
significantly reduced cyclin D1 levels, with respect to PNT 
cells transfected with negative control (C- siRNA) (-51±5 
p<0.001) (Figure 2A).
To confirm these data, we evaluated cell 
proliferation by BrdU incorporation during DNA 
synthesis. FLNA silencing significantly decreased cell 
proliferation in primary PNT cells (-37±4, p<0.05 vs 
C-siRNA (Figure 2B). These data suggest that FLNA 
promotes cell proliferation in PNTs.
To overcome the limitations due to the scarce 
availability and number of PNT cells, we used the human 
H727 cell line, as a model for typical carcinoids. To further 
investigate the promoting effects of FLNA in proliferation, 
we performed cell cycle analysis on H727 cells silenced 
for FLNA. As shown in Figure 2C FLNA knockdown 
significantly increased the percentage of H727 cells in 
the G1 phase and decreased in the S phase. Therefore, the 
cytostatic effect of FLNA silencing elicited by a decrease 
in cyclin D1 expression in PNTs cells is consistent with 
the inhibition of the cell cycle at the G1/S transition in 
H727 cell.
The tumorigenic properties of H727 cells transfected 
with C- siRNA or FLNA siRNA were compared by 
assessing their ability to grow in vitro and to form colonies.
As shown in Figure 2D, 7 days after plating, control 
H727 cells produced numerous colonies, whereas cells 
silenced for FLNA developed few and very small colonies. 
In addition, FLNA silencing significantly decreased the 
number of H727 cells (-80±3%, p<0.0001) and colony size 
(6.20 fold, p<0.001) with respect to negative control cells 
(Figure 2E, 2F).
FLNA is involved in angiogenesis increase in 
H727 cells
The VEGF pathway, implicated in angiogenesis, 
has been demonstrated to be over-expressed in 
PNTs [14], thus we evaluated FLNA implication in 
angiogenesis through links with vascular endothelial 
growth factor (VEGF). As shown in Figure 3A,3B, 
VEGF expression decreased in primary PNT cells and 
H727 cells lacking FLNA (-36±7%, p<0.05 vs C-siRNA 
and -39±9%, p<0.01 vs C-siRNA, respectively). To 
confirm this result, we measured the levels of VEGF 
secreted by H727 cells transfected with C- or FLNA 
siRNA by ELISA. After 24 hours of culture VEGF 
release was drastically reduced in H727 cells transfected 
with FLNA siRNA compared to control, suggesting 
that FLNA silencing suppressed VEGF secretion. 
These data support the key role of FLNA in promoting 
angiogenesis.
Table 1: Associations between FLNA expression and clinicopathological features in PNTs
Factor FLNA H scores (average) P-value
Age (years) **a
 ≤50 3,06547619
 >50 5,376539142
Gender **a
 M 6,021481481
 F 4,032439024
T *b
 T1 4,321891892
 T2 4,95
 T3 6,625
 T4 9
N *b
 N0 4,229038462
 N1 5,125
 N2 7,178571429
The association was identified with the appropriated statistical test, t-test or ANOVA when required.
F, female; M, male.
a t-test; b ANOVA.
T, primary tumor; N, lymph node involvement.
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Figure 2: FLNA silencing reduced PNT cell proliferation and colony formation. (A) Representative immunoblotting 
performed with antibodies raised against Cyclin D1. FLNA knock down induced a significant decrease in Cyclin D1 levels 
in primary PNT cells. The equal amount of protein was confirmed by stripping and reprobing with an anti-GAPDH antibody. 
The graph shows the quantification of Cyclin D1 normalized to GAPDH. Data represent mean ± SD of three independent 
experiments.*** =p<0.001 vs C- siRNA. (B) After FLNA silencing, we measured cell proliferation in primary PNTs cells 
incubated with BrdU for 24 h. Experiments were repeated 3 times and each determination was done in triplicate. Values 
represent mean (±SD) * =p<0.05 vs C- siRNA. (C) Cell cycle analysis by DNA content of H727 cells treated with C- siRNA 
or FLNA siRNA. H727 cell line were fixed and processed according to the DAPI labelling protocol listed on material and 
method. Single cells were gated via DAPI width and area signals to calculate G1, S phase, G2/M from a DAPI area histogram. 
Left panel represent H727 cells treated with C- siRNA, right panel represent H727 cells treated with FLNA siRNA. The 
graph shows the quantification of data from two independent experiments. Values represent mean (±SD) * =p<0.05, ** 
=p<0.01, §§§ =0.001. (D) FLNA silencing strongly decreased quantity of colonies. Microscopyimages (top panels) show 
H727 cells incubated with C-siRNA and FLNA siRNA after 7 days. Images of the cell colony assay stained with a solution 
containing 0.05% crystal violet (bottom panels). (E) To count numbers of cells, after 7 days H727 cells were incubated with 
cell quantification solution and absorbance was measured at 490 nm. Graph shows that FLNA silencing significantly decreased 
number of H727 cells with respect to C-siRNA cells. Values represent mean ±SD of 3 experiments. ****=p<0.0001 vs 
corresponding basal. (F) To measure colony surface area, 3-4 fields were randomly selected in each well. Average of colony 
area (μm2) was measured using the software ImageJ. ***=p<0.001 vs corresponding basal. Experiments were repeated at 
least 3 times. Statistical analysis was performed with t-test.
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Figure 3: Effect of FLNA on VEGF expression and in vitro release in H727 cells. (A&B) Representative immunoblot of 
VEGF demonstrates that FLNA silencing reduces VEGF expression in primary PNTs cells and H727 cells, respectively. The graph shows 
the ratio of VEGF/GAPDH normalized to C- siRNA. Experiments were repeated at least 2-3 times. *p<0.05, **p<0.01 vs C- siRNA. (C) 
ELISA analysis of VEGF release in supernatant by c-siRNA and FLNA siRNA H727 cells. All data are expressed as mean ± SD of three 
independent experiments. **=p <0.01, **=p<0.01 vs C- siRNA.
Figure 4: (A) Representative Immunoblot image shows thatFLNA interacts with Rap1. H727 lysate was immunoprecipitated with FLNA 
antibody or normal mouse IgG and the presence of Rap1 was detected using anti-Rap1 antibody. The presence of equal amounts of FLNA 
in the immunoprecipitates was confirmed by stripping and reprobing with anti-FLNA. As negative control, normal mouse IgG was used 
for the immunoprecipitation (IP). (B) Representative confocal microscopy images of fixed H727 cells stained for FLNA (green) and Rap1 
(red). The results shown are representative images of three individual experiments. Scale bar 10 μm. (C) Representative immunoblots of 
Rap1 expression in H727 cells transfected with C-siRNA or FLNA siRNA. The graph shows the ratio of Rap1/GAPDH normalized to 
C-siRNA (mean value ±SD from 3 independent experiments). **=p<0.01 vs C- siRNA.
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FLNA interacts with Rap1 in H727 cells
Since Rap1 small GTPase is involved in the control 
of cell migration and adhesion and it plays a key role 
in neuroendocrine tumors [16], we hypothesized that 
the effects of FLNA could be mediated, at least in part, 
by a modulation of Rap1 expression. To examine this 
hypothesis, we evaluated the possible interaction between 
FLNA and Rap1 by immunoprecipitation. As shown in 
Figure 4A, Rap1 interacts with FLNA in H727 cells. This 
result was confirmed by immunofluorescence analysis, in 
which FLNA co-localized with Rap1 and interestingly, 
they co-localized mainly in cellular protrusions (Figure 
4B). Interestingly, FLNA silencing increased Rap1 
expression levels in H727 cell with respect to control 
cells (+73±18%, p<0.01 vs C-siRNA) (Figure 4C), thus 
suggesting that FLNA is involved in the regulation of 
Rap1 expression.
Implication of Rap1 in FLNA effect on cell 
proliferation, cell adhesion and cell migration
To characterize the mechanism by which FLNA 
affects cell proliferation in H727 cells, we co-transfected 
Rap1 siRNA and FLNA siRNA with the aim of blocking 
the over-expression of Rap1 induced by FLNA silencing. 
FLNA silencing strongly reduced cyclin D1 expression 
and cell proliferation in H727 cells (-61±2% p<0.05 vs 
Figure 5: FLNA effect on cell proliferation, adhesion and cell migration and Rap1 involvement. (A) FLNA siRNA-treated 
cells showed a strong decrease in Cyclin D1 expression and cell proliferation in H727 cells not via Rap1. H727 cells were transfected with 
control siRNA, FLNA siRNA alone or together with Rap1 siRNA. The graph shows the quantification of Cyclin D1 normalized to GAPDH. 
Data represent mean ± SD of three independent experiments. One-way ANOVA; Bonferroni post test * =p<0.05 vs C- siRNA. (B) The 
graph shows BrdU incorporation during DNA synthesis in H727 cells transfected with C-siRNA, FLNA siRNA alone or together with Rap1 
siRNA. Data represent mean ± SD of three independent experiments. One-way ANOVA; Bonferroni post test **=p<0.01 vs C- siRNA. (C) 
H727 cells transfected with C-siRNA or FLNA siRNA alone or together with Rap1 siRNA were incubated in complete medium for 90 min 
at 37°C. Experiments carried out in H727 cells were repeated at least 4 times. The graph shows the quantification of adherent cells. Values 
represent mean (±SD). One-way ANOVA; Bonferroni post test **=p<0.01 vs C-siRNA. (D) H727 cells transfected with C-siRNA, FLNA 
siRNA alone or together with Rap1 were incubated for 24 h with serum-free medium. Migratory cells were quantified by fluorometric plate 
reader. Experiments were performed in triplicate 3 times. Values represent mean (±SD); One-way ANOVA; Bonferroni post test **=p<0.01 
vs C-siRNA.
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C-siRNA and -56±11 p<0.01, respectively), confirming 
previous results in PNT cells. However, Rap1 knock 
down did not prevent the effects on cell proliferation of 
suppressing FLNA expression (Figure 5A, 5B). This result 
suggests that FLNA promotes cell proliferation in H727 
cells, but not via Rap1.
Conversely, FLNA silencing increased cell adhesion 
(+43%±18%, p<0.01 vs C-siRNA) and decreased cell 
migration (-56±7%, p<0.01 vs C-siRNA). Interestingly, 
Rap1 silencing prevented the effects on adhesion and 
migration of suppressing FLNA expression in H727 cells 
(Figure 5C, 5D). These data suggest that FLNA effects on 
cell adhesion and migration are mediated by Rap1
DISCUSSION
Cytoskeleton protein FLNA appears as a crucial 
element in PNTs cells as demonstrated in various types 
of cancers [5, 6], in which FLNA expression is correlated 
with the cancer metastatic potential.
In this study, we first found that FLNA is expressed 
in typical PNT samples and in the appropriate cellular 
model H727 cell line. In this respect, multiple studies 
detected FLNA over-expression in human glioblastomas 
[17], in pancreatic cancer [18], salivary gland adenoid 
cystic carcinoma [19], in peripheral cholangiocarcinomas 
[20] and many others.
We also showed that FLNA expression increased 
progressively with malignant grade, as reported in several 
studies, in which FLNA expression is correlated with 
cancer aggressiveness [21]. In this respect, circulating 
FLNA has been detected in plasma samples obtained from 
breast cancer patients using a monoclonal antibody, while 
no FLNA was found in plasma from normal subjects [22].
Next, the associations between FLNA expression 
and the clinicopathological features of the patients with 
PNT were investigated. Interestingly, FLNA expression is 
significantly correlated with clinical parameters, including 
age, gender, T and N staging.
Thus, the increase of FLNA expression in malignant 
PNTs, together with the correlation between its expression 
and additional histopathologic characteristics suggests that 
FLNA may be a useful tool for individualized therapeutic 
strategy and its expression may be considered as a 
potential diagnostic marker.
The knockdown of FLNA was associated with a 
decrease in metastasis and proliferation in different cancer 
cells, including human melanoma cells [23]. In this work, 
we report that FLNA promotes PNT cell proliferation 
and colony formation, crucial mechanisms involved in 
cancer progression. In particular, we demonstrated that the 
cytostatic effect of FLNA silencing is consistent with the 
inhibition of the cell cycle at the G1/S transition in PNT 
cells, corresponding to a decrease in cyclin D1 expression. 
These results confirmed the central role of FLNA in 
tumorigenesis.
Recently, the involvement of the cytoskeletal actin-
binding proteins in angiogenesis has been suggested as 
a target for anti-neovascular cancer therapy in vitro. In 
particular, a positive relationship between FLNA and 
VEGF has been demonstrated in patients with lung cancer 
[14], suggesting that FLNA is implicated in the control 
of angiogenesis through links with VEGF. Interestingly, 
overexpression of VEGF, together with VEGF receptors, 
has been observed in PNTs, suggesting that an autocrine 
activation of VEGF pathway may be involved in PNT 
tumorigenesis and progression [2, 24]. Consistently with 
this observation, we demonstrated that FLNA silencing 
significantly decreased VEGF expression in PNT cells. 
Moreover, VEGF release was drastically reduced in H727 
cells silenced for FLNA, suggesting that FLNA silencing 
also suppressed VEGF secretion. These data support the 
key role of FLNA in promoting angiogenesis.
Increasing evidence demonstrated that FLNA is 
essential for the regulation of cell migration and adhesion 
[25, 26]. In this respect, FLNA is required for podosome 
stabilization, extracellular matrix degradation and 
three-dimensional mesenchymal migration [27]. In our 
neuroendocrine model, we demonstrated that FLNA knock-
down decreased cell migration and increased cell adhesion.
Due to its functions in the control of cell mobility, 
cell adhesion, cell proliferation, angiogenesis and colony 
formation, it is reasonable that FLNA may represent a 
biomarker for PNT diagnosis and prediction of clinical 
outcomes.
By virtue of its scaffolding function, FLNA also 
interacts with more than 90 functionally different proteins 
involved in tumorigenesis and metastasis [8, 10, 23]. In fact, 
FLNA anchors GTPase signaling proteins and coordinates 
their actin-remodeling activities, leading the formation of 
lamellipodia and filopodia [11]. In addition to the multiple 
proteins binding FLNA, we found that FLNA interacts 
with a novel downstream effector Rap1 small GTPase, 
and interestingly, these proteins colocalizes in cellular 
protrusions. In fact, Rap1 is involved in the control of cell 
migration and adhesion by enhancing integrin-mediated 
cell–matrix attachment in several cell types [12].
Mechanistically, we showed that FLNA down-
regulates the expression of Rap1 in H727 cells. Since 
Rap1 is also involved in regulating cell adhesion 
and proliferation in PNT cells [16], we speculated 
that down-regulation of Rap1 expression by FLNA 
modulates these cellular activities, essential for cancer 
progression and metastasis development. Considering 
that FLNA knockdown increased Rap1 expression, 
we evaluated whether or not Rap1 over-expression 
silencing was able to abolish the effects of FLNA 
on cell proliferation, cell adhesion and migration. 
We concluded that FLNA increased cell migration 
and decreased cell adhesion by a Rap1-dependent 
pathway, but it increased cell proliferation via a Rap1-
independent mechanism.
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These results underline the crucial role of FLNA in 
cancer progression and aggressiveness and consequently 
its potential interest in PNTs therapy. In particular, 
the involvement of FLNA pathway in mediating PNT 
progression might not only provide valuable diagnostic 
and prognostic markers, but also novel therapeutic targets.
MATERIALS AND METHODS
Pulmonary neuroendocrine tumor cell cultures
The study was approved by the local ethics 
committee. Informed consent was obtained from all 
subjects involved in the study. Human neuroendocrine 
cells were obtained from 5 typical PNTs that were 
enzymatically dissociated in DMEM containing 2 mg/
mL collagenase (Sigma–Aldrich CorporateHeadquarters 
St. Louis, MO) at 37°C for 2h. Dispersed cells were 
cultured in DMEM supplemented with 10% fetal bovine 
serum, 2 mM glutamine and antibiotics. Human typical 
bronchial carcinoid cell line H727 were purchased 
from ATCC in 2013. Cells were grown in RPMI 1640 
medium supplemented with 10% FBS, 2 mM glutamine 
and antibiotics. H727 cell line was cultured at 37°C in 
5% CO2 atmosphere. H727 were tested for mycoplasma 
contamination by using N-GARDE mycoplasma PCR 
reagent set (#EMK090020, Euroclone).
Immunohistochemistry
Immunohistochemistry experiments were performed 
on sections from 66 PNTs retrieved from the archives of 
Pathology Unit of IRCCS Ospedale Maggiore Policlinico, 
Milan, Italy. After dewaxing in Bioclear and rehydrating 
in ethanol, the sections were pretreated in a water bath set 
to 98°C in 0.01 M citrate buffer for 25 minutes. FLNA 
antibody (MAB1678, Millipore, 1:600 diluition) was 
used, and antigen-antibody detection was performed with 
the MACH1 universal polymer detection kit (Biocare 
Medical). The evaluation of immunohistochemical 
staining was blind and FLNA immunoreactivities were 
graded according to an immunohistochemical score as 
previously described [28].
FLNA and Rap1 silencing in pulmonary 
neuroendocrine cells
Gene silencing was performed in PNTs and H727 
cells using species-specific human FLNA pre-designed 
siRNA (#4392420, Invitrogen) and Rap1 siRNA (#sc-
36384 Santa Cruz), using Lipofectamine 2000 transfection 
reagent (#11668-019, Invitrogen) according to the 
manufacturer’s instruction, for 72h and 48h of incubation, 
respectively.
In order to obtain the best efficiency of FLNA 
silencing three different human FLNA silencer select pre-
designed siRNAs were tested.
Preliminary experiments to determine the optimal 
concentration of siRNAs and the kinetics of silencing 
of FLNA and Rap1 were performed. A negative control 
siRNA (C- siRNA) (AM4611, Invitrogen), a non-targeting 
sequence without significant homology to the sequence 
of human, mouse or rat transcripts, was used in each 
experiment. Western blotting was performed in each 
experiment to control the expression level of FLNA and 
Rap1 in silenced cells.
Proliferation assay
Cell proliferation was assessed by colorimetric 
measurement of 5-bromo-2’-deoxyuridine (BrdU) 
incorporation during DNA synthesis in proliferating 
cells, according to the instruction of the manufacturer, as 
previously reported [29]. Briefly, after transfection with 
FLNA siRNA, Rap1 siRNA or Rap1 together with FLNA 
siRNAs, cells were incubated with complete medium for 
24h hours and then with BrdU for 2h (cell lines) and 24h 
(primary cultures) to allow BrdU incorporation in newly 
synthesized cellular DNA. All experiments were repeated 
at least three times and each determination was done in 
triplicate.
Colony formation
After FLNA silencing, H727 cells were seeded into 
6-well plates and 96-well plates in triplicate at a density 
of 1000 cells or 250 cells, respectively, and incubated in a 
37°C for 7 days. To visualize colonies, we fixed the cells 
for 10 min with 4% PFA and then we stained cell clones 
for 30 min with a solution containing 0.05% crystal violet, 
followed by water rinses to remove excess dye. The dishes 
were then photographed.
To obtain number of cells, we incubated cells 
with cell quantification solution, according to the 
manufacturer’s protocol (#ECM570, Millipore), for 4 
hours at 37°C and then, we measured absorbance at 
490 nm. Images of H727 clones were acquired using 
brightfield microscopy with a 4X objective lens (Widefield 
IX53 Inverted, Olympus). Average of colony area is 
measured using the NIH software ImageJ.
Cell cycle analysis
Cells were cultured in 6 well plates (6 x 105 cells per 
well) with 1 ml of medium. After 72h of silencing fresh 
medium was added to perform the cell cycle analysis and 
left for 6 hours. Cells were harvested and washed twice 
in PBS 1X at 4°. Then cells were fix in 1ml of cold 80% 
ethanol adding drop wise to the pellet while vortexing and 
incubated at 4° for 30 min. After the cells were centrifuge 
at 2000rpm for 5 min to remove ethanol and then washed 
twice in PBS 1X at 4°. Finally the cells were stained for 30 
minutes in DAPI solution (PBS, 0.01% TRITON X-100, 
1 ug/ml DAPI-Invitrogen™) at RT and then DNA content 
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was read at BD FACSymphony A5. The results were 
analyzed using FlowJo® software (FlowJo LLC).
Immunoprecipitation of Rap1
H727 cells were lysed in lysis buffer in the presence 
of protease inhibitors. The homogenates were centrifuged for 
10 min at 14,000 rpm at 4°C and the supernatant incubated 
with 2 μg of FLNA antibody (H00002316-M01, Abnova, 
1:1000) and mixed overnight on a rotating wheel at 4°C.
Then 20 μl of resuspended volume of Protein 
A/G PLUS-Agarose beads (Santa Cruz) were added 
to the mix antibody-lysate and incubated at 4°C on 
a rotating device for 3 hours. Immunoprecipitates 
were collected by centrifugation at 2,500 rpm for 5 
minutes at 4°C. The pellet was washed 5 times with 
lysis buffer, each time repeating the centrifugation step 
above. After the final wash, pellet was resuspended in 
SDS sample buffer containing reducing agents and 
analyzed by Western blotting, to visualize Rap1 (07-
916, Millipore). The presence of equal amounts of 
receptor in the immunoprecipitates was confirmed by 
stripping and reprobing with anti-FLNA antibody. As 
a negative control, 2 μg of normal mouse IgG (#sc-
2025, negative control, Santa Cruz) was used for the 
immunoprecipitation (IP).
Fluorescence microscopy
H727 cells were fixed with 4% paraformaldehyde 
for 10 minutes, washed several times in PBS and treated 
with 0.1% Triton X-100 buffer. After blocking with 2% 
BSA and 5% NGS in PBS for 1 h, cells were incubated 
with anti-FLNA (MAB1678, 1:200, Millipore) and anti-
Rap1 (1:50, 07-916, Millipore) antibodies and then stained 
with Alexa Fluor 488-conjugated secondary antibody and 
AlexaFluor 546-conjugated secondary (1:1000, Invitrogen, 
Carlsbad, CA) for 1h at room temperature.
Coverslips were mounted on glass slides with 
one drop of liquid mountant (ProLong® Gold Antifade 
Mountant, ThermoFisher). All images were collected 
using Olympus Fluoview FV1000 confocal microscope.
Cyclin D1 and Rap1 western blotting
To analyze cyclin D1 expression level, H727 cells 
were treated with C- siRNA, FLNA siRNA, or Rap1 
siRNA together with FLNA siRNA, then serum starved 
for 24h and incubated with complete medium for 6h at 
37°C. Cells were then lysed in lysis buffer in the presence 
of protease inhibitors. Proteins were separated on SDS/
polyacrylamide gels and transferred to a nitrocellulose filter. 
A 1:1000 dilution of anti-cyclin D1 was used as primary 
antibody (ENT1173, Elabscience, Bethesda, MD) and an 
antirabbit horseradish peroxidase-linked antibody was 
used as secondary antibody. To analyze Rap1 expression 
level, H727 cells were treated with C-siRNA and FLNA 
siRNA. Cells were then lysed in lysis buffer in the presence 
of protease inhibitors. Proteins were separated on SDS/
polyacrylamide gelsand transferred to a nitrocellulose 
filter. The 1:1000 dilution of anti-Rap1 and an antirabbit 
horseradish peroxidase- linked antibody were used. GAPDH 
(AM4300, Ambion, 1:2000) was used as housekeeping.
VEGF protein expression
To study VEGF expression, primary PNTs cell or 
H727 cells were transfected with FLNA siRNA or negative 
control siRNA for 72h and incubated with complete 
medium for 24 h at 37°C. Cells were then lysed in lysis 
buffer in the presence of protease inhibitors. Proteins were 
separated on SDS/polyacrylamide gels and transferred to 
a nitrocellulose filter. The 1:1000 dilution of anti-VEGF 
(ab46154, Abcam, UK) and an antirabbit horseradish 
peroxidase-linked antibody were used. GAPDH was used 
as housekeeping.
To analyse VEGF secretion, H727 cells were 
plated in 24-well tissue culture plates and incubated 
with FLNA siRNA or negative control siRNA for 72 
h. After, fresh medium was added for 24h and then 
supernatants were collected. Media were analyzed by a 
commercially available sandwich human VEGF ELISA kit 
(DuoSet ELISA, R&D), according to the manufacturer’s 
instructions. Assays were performed in triplicate for three 
independent experiments and the results were reported as 
picograms (pg) of VEGF per ml.
Cell adhesion assay
H727 cells silenced for FLNA siRNA or Rap1 
siRNA together with FLNA siRNA were plated onto a 
collagen type IV-coated 48-well plate and incubated with 
complete medium for 90 min at 37°C, as by manufacturer’s 
protocol (CBA-061, Cell Biolabs INC). Briefly, 
nonadherent cells were removed by gently washing plates 
4-5 times with PBS, adherent cells were lysed with lysis 
buffer and subsequently detected with CyQuant® GR Dye 
(Cell Biolabs INC). Finally, each extracted sample was 
quantified by measuring fluorescence with a fluorescence 
plate reader at 480 nm/520 nm. The experiment was 
performed four times in quadruplicate.
Cell migration assay
H727 cells, transfected with negative control 
siRNA, FLNA siRNA or Rap1 together with FLNA 
siRNAs were plated in polycarbonate membrane plate 
(MDCBA-106, Cell Biolabs INC) in serum-free medium 
and placed into the feeder tray, containing chemoattractant 
solution, according to the instruction of the manufacturer. 
After 24 hours of incubation at 37°C, migratory cells 
were first dissociated from the membrane, then stained 
and quantified after extraction using a fluorometric plate 
reader.
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Statistical analysis
The results were expressed as the mean ± SD. A 
paired two-tailed Student’s test was used to detect the 
significance between two series of data. P<0.05 was 
accepted as statistically significant.
One-way ANOVA analysis was used to compare 
three or more groups, followed by Bonferroni post-hoc 
test. Calculations were performed by GraphPad Prism 4.0 
software (GraphPad Software, Inc., La Jolla, CA). P<0.05 
was accepted as statistically significant.
Abbreviations
FLNA: filamin-A; PNT: pulmonary neuroendocrine 
tumor; HIF-1α: hypoxia-inducible factors-1α; VEGF: 
vascular endothelial growth factor; siRNA: small 
interfering RNA; BrdU: 5-bromo-2’-deoxyuridine; IP: 
immunoprecipitation; GAPDH: Glyceraldehyde-3-
Phosphate Dehydrogenase.
Author contributions
Conception and design: Eleonora Vitali, Andrea 
Lania.
Development of methodology: Eleonora Vitali, 
Valeria Cambiaghi.
Acquisition of data: Eleonora Vitali, Pierluigi 
Novellis, Giulia Veronesi, Stefano Ferrero, Ilena Boemi, 
Lorenzo Rosso.
Analysis and interpretation of data (e.g., statistical 
analysis, biostatistics, computational analysis): Eleonora 
Vitali.
Writing, review, and/or revision of the manuscript: 
Eleonora Vitali, Giovanna Mantovani, Anna Spada, 
Alloisio Marco, Andrea Lania.
Administrative, technical, or material support (i.e., 
reporting or organizing data, constructing databases): 
Eleonora Vitali, Ilena Boemi, Lorenzo Rosso.
Study supervision: Andrea Lania.
ACKNOWLEDGMENTS
The authors are grateful to Dr. Sara Piccini for 
editorial assistance.
CONFLICTS OF INTEREST
The authors declare no potential conflicts of interest.
GRANT SUPPORT
This work has been supported by AIRC grant 
(AL, IG-13051) and Fellowship to E.V. and P. N. from 
Fondazione Umberto Veronesi.
REFERENCES
1. Travis WD. Pathology and diagnosis of neuroendocrine 
tumors: lung neuroendocrine. Thorac Surg Clin. 2014; 24: 
257–66. https://doi.org/10.1016/j.thorsurg.2014.04.001.
2. Gridelli C, Rossi A, Airoma G, Bianco R, Costanzo R, 
Daniele B, Chiara GD, Grimaldi G, Irtelli L, Maione 
P, Morabito A, Piantedosi FV, Riccardi F. Treatment of 
pulmonary neuroendocrine tumours: state of the art and 
future developments. Cancer Treat Rev. 2013; 39: 466–72. 
https://doi.org/10.1016/j.ctrv.2012.06.012.
3. Noel-Savina E, Descourt R. Focus on treatment of lung 
carcinoid tumor. Onco Targets Ther. 2013; 6: 1533–7. 
https://doi.org/10.2147/OTT.S32464.
4. Jiang X, Yue J, Lu H, Campbell N, Yang Q, Lan S, Haffty 
BG, Yuan C, Shen Z. Inhibition of filamin-A reduces cancer 
metastatic potential. Int J Biol Sci. 2012; 9: 67–77. https://
doi.org/10.7150/ijbs.5577.
5. Savoy RM, Ghosh PM. The dual role of filamin A in cancer: 
can’t live with (too much of) it, can’t live without it. Endocr 
Relat Cancer. 2013; 20: R341–56. https://doi.org/10.1530/
ERC-13-0364.
6. Yue J, Huhn S, Shen Z. Complex roles of filamin-A 
mediated cytoskeleton network in cancer progression. Cell 
Biosci. 2013; 3: 7. https://doi.org/10.1186/2045-3701-3-7.
7. Djinovic-Carugo K, Carugo O. Structural portrait of filamin 
interaction mechanisms. Curr Protein Pept Sci. 2010; 11: 
639–50. https://doi.org/CPPS-75.
8. Zhou AX, Hartwig JH, Akyürek LM. Filamins in cell 
signaling, transcription and organ development. Trends 
Cell Biol. 2010; 20: 113–23. https://doi.org/10.1016/j.
tcb.2009.12.001.
9. Razinia Z, Mäkelä T, Ylänne J, Calderwood D a. 
Filamins in mechanosensing and signaling. Annu Rev 
Biophys. 2012; 41: 227–46. https://doi.org/10.1146/
annurev-biophys-050511-102252.
10. Nakamura F, Stossel TP, Hartwig JH. The filamins: 
organizers of cell structure and function. Cell Adhes Migr. 
2011; 5: 160–9. https://doi.org/10.4161/cam.5.2.14401.
11. Ohta Y, Suzuki N, Nakamura S, Hartwig JH, Stossel TP. 
The small GTPase RalA targets filamin to induce filopodia. 
Proc Natl Acad Sci U S A. 1999; 96: 2122–8. https://doi.
org/10.1073/pnas.96.5.2122.
12. Caron E. Cellular functions of the Rap1 GTP-binding 
protein: a pattern emerges. J Cell Sci. 2003; 116: 435–40. 
https://doi.org/10.1242/jcs.00238.
13. Zheng X, Zhou AX, Rouhi P, Uramoto H, Borén J, Cao Y, 
Pereira T, Akyürek LM, Poellinger L. Hypoxia-induced 
and calpain-dependent cleavage of filamin A regulates the 
hypoxic response. Proc Natl Acad Sci U S A. 2014; 111: 
2560–5. https://doi.org/10.1073/pnas.1320815111.
Oncotarget77340www.impactjournals.com/oncotarget
14. Uramoto H, Akyürek LM, Hanagiri T. A positive 
relationship between filamin and VEGF in patients with 
lung cancer. Anticancer Res. 2010; 30: 3939–44.
15. Semenza GL. Hypoxia-inducible factors: mediators of 
cancer progression and targets for cancer therapy. Trends 
Pharmacol Sci. 2012; 33: 207–14. https://doi.org/10.1016/j.
tips.2012.01.005.
16. Vitali E, Cambiaghi V, Spada A, Tresoldi A, Zerbi A, 
Peverelli E, Carnaghi C, Mantovani G, Lania AG. cAMP 
effects in neuroendocrine tumors: the role of Epac and PKA 
in cell proliferation and adhesion. Exp Cell Res. 2015; 339: 
241–51. https://doi.org/10.1016/j.yexcr.2015.11.011.
17. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino 
S, Passaniti A, Menon J, Walling J, Bailey R, Rosenblum 
M, Mikkelsen T, Fine HA. Neuronal and glioma-derived 
stem cell factor induces angiogenesis within the brain. 
Cancer Cell. 2006; 9: 287–300. https://doi.org/10.1016/j.
ccr.2006.03.003.
18. Logsdon CD, Simeone DM, Binkley C, Arumugam 
T, Greenson JK, Giordano TJ, Misek DE, Hanash S. 
Molecular profiling of pancreatic adenocarcinoma and 
chronic pancreatitis identifies multiple genes differentially 
regulated in pancreatic cancer. Cancer Res. 2003; 63: 2649–
57. https://doi.org/10.3322/canjclin.53.1.5.
19. Frierson HF, El-Naggar AK, Welsh JB, Sapinoso LM, Su 
AI, Cheng J, Saku T, Moskaluk CA, Hampton GM. Large 
scale molecular analysis identifies genes with altered 
expression in salivary adenoid cystic carcinoma. Am 
J Pathol. 2002; 161: 1315–23. https://doi.org/10.1016/
S0002-9440(10)64408-2.
20. Guedj N, Zhan Q, Perigny M, Rautou PE, Degos F, 
Belghiti J, Farges O, Bedossa P, Paradis V. Comparative 
protein expression profiles of hilar and peripheral hepatic 
cholangiocarcinomas. J Hepatol. 2009; 51: 93–101. https://
doi.org/10.1016/j.jhep.2009.03.017.
21. Uhlen MA. Human protein atlas for normal and 
cancer tissues based on antibody proteomics. Mol Cell 
Proteomics. 2005; 4: 1920–32. https://doi.org/10.1074/mcp.
M500279-MCP200.
22. Browne KA, Johnstone RW, Jans DA, Trapani JA. 
Filamin (280-kDa actin-binding protein) is a caspase 
substrate and is also cleaved directly by the cytotoxic T 
lymphocyte protease granzyme B during apoptosis. J Biol 
Chem. 2000; 275: 39262–6. https://doi.org/10.1074/jbc.
C000622200.
23. Zhang K, Zhu T, Gao D, Zhang Y, Zhao Q, Liu S, Su T, 
Bernier M, Zhao R. Filamin A expression correlates with 
proliferation and invasive properties of human metastatic 
melanoma tumors: implications for survival in patients. J 
Cancer Res Clin Oncol. 2014; 140: 1913–26. https://doi.
org/10.1007/s00432-014-1722-3.
24. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, 
Capella C. Localization of vascular endothelial growth 
factor and its receptors in digestive endocrine tumors: 
correlation with microvessel density and clinicopathologic. 
Hum Pathol. 2003; 34: 18–27. https://doi.org/10.1053/
hupa.2003.56.
25. D’Addario M, Arora PD, Fan J, Ganss B, Ellen RP, 
McCulloch CA. Cytoprotection against mechanical forces 
delivered through β 1 integrins requires induction of 
Filamin A. J Biol Chem. 2001; 276: 31969–77. https://doi.
org/10.1074/jbc.M102715200.
26. Meyer SC, Sanan DA, Fox JE. Role of actin-binding protein 
in insertion of adhesion receptors into the membrane. J 
Biol Chem. 1998; 273: 3013–20. https://doi.org/10.1074/
jbc.273.5.3013.
27. Guiet R, Vérollet C, Lamsoul I, Cougoule C, Poincloux 
R, Labrousse A, Calderwood DA, Glogauer M, Lutz PG, 
Maridonneau-Parini I. Macrophage mesenchymal migration 
requires podosome stabilization by Filamin A. J Biol 
Chem. 2012; 287: 13051–62. https://doi.org/10.1074/jbc.
M111.307124.
28. Vitali E, Cambiaghi V, Zerbi A, Carnaghi C, Colombo P, 
Peverelli E, Spada A, Mantovani G, Lania AG. Filamin-A 
is required to mediate SST2 effects in pancreatic 
neuroendocrine tumours. Endocr Relat Cancer. 2016; 23: 
181–90. https://doi.org/10.1530/ERC-15-0358.
29. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni 
S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, 
Ferrante E, Bosari S, Beck-Peccoz P, Spada A. Proliferation 
of transformed somatotroph cells related to low or absent 
expression of protein kinase A regulatory subunit 1A 
protein. Cancer Res. 2004; 64: 9193–8. https://doi.
org/10.1158/0008-5472.CAN-04-1847.
